Oryzon Genomics — ASH 2025: Promising iadademstat updates

Oryzon Genomics announced the presentation of promising updates for two clinical studies involving iadademstat at the American Society of Hematology (ASH) 67th Annual Meeting. Notably, a Phase Ib trial (ALICE-2) testing the candidate in combination with azacitidine and venetoclax showed a 100% overall response rate (ORR) across 10 newly diagnosed acute myeloid leukaemia (AML) patients, and a composite complete remission (CCR) rate of 90%. The second update corresponds to the lead FRIDA programme (iadademstat plus gilteritinib in FLT3-mutant relapsed/refractory (r/r) AML), showing a CCR rate of 67% across 15 evaluable patients at the selected dose level. Importantly, across both studies, iadademstat was safe and well tolerated, which, alongside the encouraging efficacy data, positions it favourably for further development efforts, in our view. Oryzon is exploring partnership opportunities for iadademstat to unlock its full value.